Immuno-chemotherapy in Metastatic Renal Cell Carcinoma: Long-Term Results from the Rambam and Linn Medical Centers, Haifa, Israel
| Autor: | A. Kuten, Eliahu Gez, R. Rubinov, D. Gaitini, A. Stein, T. Mashiach, L.-A. Best, O. Native, S. Meretyk |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.medical_treatment Vinblastine Gastroenterology Metastasis Renal cell carcinoma Internal medicine Antineoplastic Combined Chemotherapy Protocols Carcinoma medicine Humans Pharmacology (medical) Prospective Studies Neoplasm Metastasis Carcinoma Renal Cell Aged Aged 80 and over Pharmacology Performance status business.industry Interferon-alpha Middle Aged medicine.disease Kidney Neoplasms Nephrectomy Surgery Infectious Diseases Oncology Localized disease Female Fluorouracil Immunotherapy business Kidney cancer Interleukin-1 Kidney disease |
| Zdroj: | Journal of Chemotherapy. 19:79-84 |
| ISSN: | 1973-9478 1120-009X |
| DOI: | 10.1179/joc.2007.19.1.79 |
| Popis: | Nephrectomy, immuno-chemotherapy and resection of residual disease have been the treatment of choice for patients with metastatic renal cell carcinoma during the past decades. The aim of this study was to report the long-term results of this treatment approach. Sixty-two patients with metastatic renal cell carcinoma participated in a Phase II study. At diagnosis, 32 patients had localized disease, 30 had metastatic disease and 53 underwent nephrectomy. Metastatic sites were lungs, lymph nodes, bones and liver. Immuno-chemotherapy consisted of: interleukin-2, interferon alpha, 5-fluorouracil and vinblastine. All patients were evaluated for toxicity and response to treatment. CR was achieved in 4 patients and PR in 14. Seven patients, with maximum response to immuno-chemotherapy underwent resection of residual tumor and reached CR. Therefore, CR was achieved in 11 patients (18%) with a median survival of +67 months. Flu-like symptoms were the common side effects. Performance status and histology type significantly affected survival. Nephrectomy, immuno-chemotherapy and resection of residual disease are recommended for patients with metastatic renal cell carcinoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|